NAUT

Nautilus Biotechnology announced it will receive up to $6 million as part of a $51.7 million ARPA-H-funded SEEDS consortium led by Buck Institute and Georgetown University. The consortium aims to predict protein misfolding and develop diagnostics and therapeutics for neurodegenerative diseases and cancer. Nautilus will deploy its Voyager Platform to measure proteoforms in Alzheimer's disease and Ewing sarcoma research.

Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million and net loss of $15.6 million. The company published research in Nature Methods demonstrating its Iterative Mapping technology, shared early oncology proteoform assay data, and announced participation in an ARPA-H-funded SEEDS consortium with up to $6 million in expected funding to measure proteoforms in Alzheimer's disease and cancer research.

Nautilus Biotechnology announced it will report third quarter 2026 financial results on October 27, 2026, followed by a management webcast at 5:30 a.m. PT. The company, headquartered in Seattle, is a development-stage life sciences firm focused on single-molecule protein analysis and proteomics platform technology.